Palivizumab
Pronouncation: (pal-eh-VIZ-u-mab)Class: Monoclonal antibody
Trade Names:
Synagis
- Powder for injection, lyophilized 50 mg
- Powder for injection, lyophilized 100 mg
Pharmacology
Feedback for Palivizumab
Compare with other drugs. |
Neutralizing and fusion-inhibitory activity against respiratory syncytial virus (RSV), inhibiting RSV replication.
Pharmacokinetics
Elimination
The t ½ is 20 days in children younger than 24 mo of age.
Indications and Usage
Prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.
Contraindications
Standard considerations.
Dosage and Administration
ChildrenIM 15 mg/kg monthly through the RSV season. Preferably administer in anterolateral aspect of thigh. Avoid gluteal injections because of risk of damage to sciatic nerve. Give doses more than 1 mL in divided doses.
For IM administration only. Not for intra-arterial, intradermal, subcutaneous, or IV administration.
Storage/Stability
Store unopened vials in refrigerator (36° to 46°F). Do not freeze.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Dermatologic
Rash.
EENT
Otitis media, rhinitis (at least 1%).
GI
Diarrhea; vomiting; gastroenteritis.
Hepatic
Increased AST (at least 1%).
Respiratory
Upper respiratory tract infection (at least 1%); cough; wheezing.
Miscellaneous
Fever (at least 1%); hypersensitivity including dyspnea, cyanosis, respiratory failure, urticaria, pruritus, angioedema, hypotonia, and unresponsiveness (postmarketing).
Precautions
Pregnancy
Category C .
Hypersensitivity
Severe hypersensitivity reactions on initial exposure and re-exposure to palivizumab rarely have been reported. Monitor patient for signs and symptoms of allergic reaction. Immediately inform health care provider if anaphylaxis or any other severe reaction occurs. Be prepared to treat appropriately.
Administration
Administer with caution to patients with thrombocytopenia or any coagulation disorder caused by risk of bleeding at IM injection site.
Adults
Not indicated for adult use.
Cardiopulmonary bypass
Palivizumab serum levels are decreased after cardiopulmonary bypass. Administer a dose of palivizumab as soon as possible after the cardiopulmonary bypass procedure, even if sooner than a month from the previous dose. Thereafter, doses should be administered monthly.
Patient Information
- Advise family or caregiver that medication will be prepared and administered by a health care provider in a health care setting.
- Educate family or caregiver of importance of monthly injection in helping to prevent RSV infection during the RSV season.
- Advise family or caregiver to report any of the following to health care provider: injection site reactions; fever or other signs of infection; sore throat; rash; itching or hives; swelling of the face, lips, eyes, or tongue; diarrhea; wheezing; shortness of breath; difficulty breathing.
| Link to this page | ![]() |
Printable Version | ![]() |
Email Page | ![]() |
Add to my drug list |
More Palivizumab resources:
Palivizumab - Includes detailed dosage instructions.













